Drawing for SEMFRENA

USPTO serial 79290200

SEMFRENA

Reviewed by CopyMark Law Group

Reg. 6285435Status 700Renewal
Filing date
Status date
Registration date
Mar 9, 2021
Examiner
BUTLER, MIDGE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with SEMFRENA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 9, 2026REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 5, 2021FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 16, 2021FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 16, 2021FIMPFINAL DISPOSITION PROCESSED—
Jun 9, 2021FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 9, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 22, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 22, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 2, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 19, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 4, 2020RFNTREFUSAL PROCESSED BY IB—
Sep 16, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 16, 2020RFRRREFUSAL PROCESSED BY MPU—
Sep 9, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 25, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 25, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 25, 2020ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Aug 25, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 25, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 25, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 18, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 17, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 17, 2020DOCKASSIGNED TO EXAMINER—
Aug 4, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 31, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 30, 2020LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Jul 23, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance